Username:
Password:
Enter your email below to subscribe to our Health & Biotech News Digest.

All News

May 18, 2010
Lentigen Awarded Phase I STTR Grant for Hunter Syndrome
GAITHERSBURG, Md., May 18 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business technology transfer (STTR) g Read More...
Filed Under: GBP Captial News



May 04, 2010
Lentigen Spurring Innovation in AIDS Vaccine Development
WASHINGTON, D.C. – As Tim Ravenscroft reflected on the lessons he’s learned during decades in the pharmaceutical, biotech and HIV/AIDS fields at a recent Congressional Biomedical Research Caucus briefing on Capitol Hill, two of his statements reverberated in my mind: First, there Read More...
Filed Under: GBP Captial News



Apr 22, 2010
Lentigen and IAVI to Collaborate on Design of Novel AIDS Vaccine Candidate
The International AIDS Vaccine Initiative (IAVI) and Lentigen today announced a collaboration to design a preventive AIDS vaccine based on Lentigen's technology. The candidate AIDS vaccine will be devised to safely mimic biological aspects of HIV infection and tested first in pre-clinical studie Read More...
Filed Under: GBP Captial News



Mar 17, 2010
The Flexstent Femoropopliteal Self-Expanding Stent
  When lifestyle changes and/or medication alone are not an effective treatment for peripheral artery disease (PAD), endovascular or surgical procedures become an option. Endovascular devices and surgical treatment for PAD represent a major challenge for physicians treating superfi Read More...
Filed Under: GBP Captial News



Sep 29, 2009
Flexible Stenting Solutions, Inc. Receives Conditional IDE Approval For FlexStent(R) Femoropopliteal Self Expanding Stent System
Flexible Stenting Solutions Inc. ("FSS"), a leading developer of next generation peripheral arterial and biliary stents, announced that it has received Conditional Investigational Device Exemption (IDE) approval for its FlexStent® Femoropopliteal Self Expanding Stent System. With this approval, FSS Read More...
Filed Under: GBP Captial News



Sep 17, 2009
Flexible Stenting Solutions, Inc. Receives 510(k) Clearance for FlexStent Biliary Self Expanding Stent System
EATONTOWN, N.J.--(Business Wire)--Flexible Stenting Solutions Inc. ("FSS"), a leading developer of next generationperipheral arterial and biliary stents, received 510(k) clearance for the FlexStent® Biliary Self Expanding Stent System. The FlexStent® Biliary Self Expanding Stent System is indica Read More...
Filed Under: GBP Captial News



Aug 24, 2009
Flexible Stenting Solutions Inc. and Micrus Endovascular Sign Licensing and Development Agreement for Flow Diversion Technology
SAN JOSE, Calif.--(BUSINESS WIRE)--Micrus Endovascular Corporation (Nasdaq: MEND - News) and privately held Flexible Stenting Solutions Inc. of Eatontown, N.J., today announced the signing of an exclusive agreement to jointly develop a flow diversion technology for neurovascular indicati Read More...
Filed Under: GBP Captial News



Jun 25, 2009
Lentigen Collaborator Case Western Reserve University Receives $5M From Third Frontier Commission for the Center for Stem Cell & Regenerative Medicine
CLEVELAND, June 25 /PRNewswire-USNewswire/ -- The Center for Stem Cell & Regenerative Medicine (CSCRM), comprised of Case Western Reserve University (CWRU), Cleveland Clinic (CC), University Hospitals (UH), and Athersys, Inc. has received $5 million from Ohio's Third Frontier Commission Read More...
Filed Under: Company News



Feb 04, 2009
Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
GAITHERSBURG, Md. and ATLANTA, Feb 4 -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, and Expression Therapeutics, a biotechnology company specializing in factor VIII-based therapeutics, today announced Read More...
Filed Under: Company News



Jan 21, 2009
Flexible Stenting Solutions, Inc. Receives CE Mark for New FlexStent Femoropopliteal Self Expanding Stent System
EATONTOWN, N.J. - January 21, 2009 - Flexible Stenting Solutions, Inc. ("FSS"), a leading developer of next-generation flexible stents, announced today it has received CE Mark (Conformite Europeene) for its FlexStent™ Femoropopliteal Self Expanding Stent System. Stent sizes include a complet Read More...
Filed Under: Company News



53 results:

1234...6>>


© 2007 GBP Capital. All Rights Reserved. Legal | Privacy Statement | Sitemap